March 05, 2015 11:50 AM ET


Company Overview of Akesis Pharmaceuticals, Inc.

Company Overview

Akesis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of Type 2 diabetes. Its products include AKP-020, a vanadium-based monotherapy that is in Phase IIa clinical trial for the treatment for Type 2 diabetes. Akesis Pharmaceuticals has a license agreement with the University of British Columbia (UBC) to use, commercialize, and sublicense technology owned by UBC relating to the treatment of diabetes and other related disorders. The company was founded in 1990 and is based in La Jolla, California. On January 30, 2009, Akesis Pharmaceuticals Inc filed a voluntary petition for liquidation under ...

888 Prospect Street

Suite 320

La Jolla, CA 92037

United States

Founded in 1990

2 Employees





Key Executives for Akesis Pharmaceuticals, Inc.

Akesis Pharmaceuticals, Inc. does not have any Key Executives recorded.

Akesis Pharmaceuticals, Inc. Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Akesis Pharmaceuticals For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Akesis Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Epigenetx, LLC United States
Bio-Botanica, Inc. United States
BiologicsMD, LLC United States
Avidia Nutrition, Inc. United States
Smith-Collins Pharmaceutical, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Akesis Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at